Condition
ESR1 Gene Mutation clinical trials and research
As of November 12, 2026, Find a Trial lists 5 ESR1 Gene Mutation clinical trials that are recruiting, at sites in 11 countries (most in United States (2), Greece (2), China (1)). 1 was first registered in the last 30 days. By phase: Phase 2 (1), Early Phase 1 (1), Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 1New in 30 days
- 11Countries
Newest ESR1 Gene Mutation clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| ESR1 Mutations in Metastatic Hormone Receptor‑Positive Breast Cancer in Greece | — | Athens | Recruiting | Oct 27, 2026 |
| Capecitabine with or without elacestrant for ER-positive advanced breast cancer | Phase 2 | Boston, Massachusetts | Recruiting | Oct 29, 2025 |
| Observing treatment outcomes for Chinese patients with advanced breast cancer and ESR1 mutations | — | Suzhou, Jiangsu | Recruiting | Aug 12, 2024 |
| Combination treatment for advanced ER-positive breast cancer with ESR1 mutations | Phase 3 | Innsbruck and 103 other locations | Recruiting | Apr 24, 2024 |
| Using imaging to optimize tamoxifen treatment for metastatic breast cancer | Early Phase 1 | Madison, Wisconsin and 1 other locations | Recruiting | Nov 22, 2019 |
All recruiting trials (5)
-
ESR1 Mutations in Metastatic Hormone Receptor‑Positive Breast Cancer in Greece
This study tests how common ESR1 mutations are in Greek patients with advanced hormone receptor–positive, HER2‑negative breast cancer and looks at how those mutations relate to disease features and real-world treatment patterns.
-
Capecitabine with or without elacestrant for ER-positive advanced breast cancer
This trial will try adding elacestrant to capecitabine to see if it helps people with ER-positive, HER2-negative advanced breast cancer that stopped responding to CDK4/6 inhibitors.
-
Observing treatment outcomes for Chinese patients with advanced breast cancer and ESR1 mutations
This study looks at how well different treatments work for Chinese patients with advanced breast cancer and specific gene mutations who haven't had success with previous hormone therapy.
-
Combination treatment for advanced ER-positive breast cancer with ESR1 mutations
This study is testing if a new combination of two drugs can help people with advanced ER-positive breast cancer that has specific mutations live longer and keep their cancer under control.
-
Using imaging to optimize tamoxifen treatment for metastatic breast cancer
This study is testing if special imaging can help doctors find the best dose of tamoxifen for patients with metastatic breast cancer who have certain mutations and may not respond well to standard treatment.
Related topics
Quick answers
How many ESR1 Gene Mutation clinical trials are recruiting right now?
5, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 11 countries. The most sites are in United States (2 trials), Greece (2 trials), China (1 trial), Austria (1 trial), Brazil (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 1, Early Phase 1: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.